228 related articles for article (PubMed ID: 37062643)
1. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials.
Fan G; Guo DL
Eur J Intern Med; 2023 Aug; 114():49-57. PubMed ID: 37062643
[TBL] [Abstract][Full Text] [Related]
2. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis.
Theofilis P; Antonopoulos AS; Katsimichas T; Oikonomou E; Siasos G; Aggeli C; Tsioufis K; Tousoulis D
Pharmacol Res; 2022 Jun; 180():106243. PubMed ID: 35523389
[TBL] [Abstract][Full Text] [Related]
3. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
5. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function.
Shi FH; Li H; Shen L; Xu L; Ge H; Gu ZC; Lin HW; Pu J
J Clin Endocrinol Metab; 2022 Mar; 107(4):1191-1203. PubMed ID: 34791312
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies.
Carluccio E; Biagioli P; Reboldi G; Mengoni A; Lauciello R; Zuchi C; D'Addario S; Bardelli G; Ambrosio G
Cardiovasc Diabetol; 2023 Sep; 22(1):235. PubMed ID: 37660005
[TBL] [Abstract][Full Text] [Related]
7. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials.
Dhingra NK; Mistry N; Puar P; Verma R; Anker S; Mazer CD; Verma S
ESC Heart Fail; 2021 Dec; 8(6):4693-4700. PubMed ID: 34623032
[TBL] [Abstract][Full Text] [Related]
9. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
[TBL] [Abstract][Full Text] [Related]
10. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
[TBL] [Abstract][Full Text] [Related]
12. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
13. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Fernandes GC; Fernandes A; Cardoso R; Penalver J; Knijnik L; Mitrani RD; Myerburg RJ; Goldberger JJ
Heart Rhythm; 2021 Jul; 18(7):1098-1105. PubMed ID: 33757845
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
15. Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction.
Shen X; Shen X
ESC Heart Fail; 2022 Aug; 9(4):2239-2248. PubMed ID: 35642772
[TBL] [Abstract][Full Text] [Related]
16. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
17. The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Usman MS; Januzzi JL; Anker SD; Salman A; Parikh PB; Adamo M; Filippatos G; Khan MS; Lala A; Verma S; Metra M; Butler J
Eur J Heart Fail; 2024 Feb; 26(2):373-382. PubMed ID: 38235936
[TBL] [Abstract][Full Text] [Related]
18. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
Bryan Richard S; Huang B; Liu G; Yang Y; Luo S
Clin Cardiol; 2021 Apr; 44(4):463-471. PubMed ID: 33638556
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.
Adamou A; Chlorogiannis DD; Kyriakoulis IG; Stamatiou I; Koukousaki D; Kardoutsos I; Sagris D; Doehner W; Ntaios G
Intern Emerg Med; 2024 Mar; 19(2):565-573. PubMed ID: 38353880
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
